Benzinga | May 26, 2021 09:10AM EDT

Natera To Present At American Society Of Clinical Oncology Meeting Jun. 4-8

Natera, Inc. (NASDAQ:NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new clinical data on its personalized and tumor-informed molecular residual disease (MRD) assay, Signatera, at the 2021 American Society of Clinical Oncology (ASCO) annual meeting, taking place June 4-8, 2021. Two additional studies were presented at the 2021 American Association for Cancer Research (AACR) annual meeting that took place April 9-14, 2021.